
Site burden is now measured through satisfaction surveys, in-the-moment check-ins, and adoption patterns, but each method catches a different moment, and the gaps between them decide whether teams can act before burden becomes risk.
The Federal Drug Administration has decided to extend the Cooperative Research and Development Agreement with CluePoints until October 2021. The extension will include research focused on real-world evidence and 'moderators of treatment effect'.
For more information, click






